Cargando…
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial
OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metfor...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515672/ https://www.ncbi.nlm.nih.gov/pubmed/28185288 http://dx.doi.org/10.1002/lary.26489 |
_version_ | 1783251018805411840 |
---|---|
author | Curry, Joseph Johnson, Jennifer Tassone, Patrick Vidal, Marina Domingo Menezes, Diana Whitaker Sprandio, John Mollaee, Mehri Cotzia, Paolo Birbe, Ruth Lin, Zhao Gill, Kurren Duddy, Elizabeth Zhan, Tingting Leiby, Benjamin Reyzer, Michelle Cognetti, David Luginbuhl, Adam Tuluc, Madalina Martinez‐Outschoorn, Ubaldo |
author_facet | Curry, Joseph Johnson, Jennifer Tassone, Patrick Vidal, Marina Domingo Menezes, Diana Whitaker Sprandio, John Mollaee, Mehri Cotzia, Paolo Birbe, Ruth Lin, Zhao Gill, Kurren Duddy, Elizabeth Zhan, Tingting Leiby, Benjamin Reyzer, Michelle Cognetti, David Luginbuhl, Adam Tuluc, Madalina Martinez‐Outschoorn, Ubaldo |
author_sort | Curry, Joseph |
collection | PubMed |
description | OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. STUDY DESIGN: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full‐treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. METHODS: Immunohistochemistry (IHC) for the metabolic markers caveolin‐1 (CAV1), B‐galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki‐67 IHC, were performed in pre‐ and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. RESULTS: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4‐fold postmetformin (P < 0.05), as measured by MSI. CONCLUSION: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1808–1815, 2017 |
format | Online Article Text |
id | pubmed-5515672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55156722018-08-01 Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial Curry, Joseph Johnson, Jennifer Tassone, Patrick Vidal, Marina Domingo Menezes, Diana Whitaker Sprandio, John Mollaee, Mehri Cotzia, Paolo Birbe, Ruth Lin, Zhao Gill, Kurren Duddy, Elizabeth Zhan, Tingting Leiby, Benjamin Reyzer, Michelle Cognetti, David Luginbuhl, Adam Tuluc, Madalina Martinez‐Outschoorn, Ubaldo Laryngoscope Head and Neck OBJECTIVE: The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. STUDY DESIGN: Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full‐treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. METHODS: Immunohistochemistry (IHC) for the metabolic markers caveolin‐1 (CAV1), B‐galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki‐67 IHC, were performed in pre‐ and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. RESULTS: Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4‐fold postmetformin (P < 0.05), as measured by MSI. CONCLUSION: Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1808–1815, 2017 John Wiley and Sons Inc. 2017-02-10 2017-08 /pmc/articles/PMC5515672/ /pubmed/28185288 http://dx.doi.org/10.1002/lary.26489 Text en © 2017 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of The American Laryngological, Rhinological and Otological Society, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Head and Neck Curry, Joseph Johnson, Jennifer Tassone, Patrick Vidal, Marina Domingo Menezes, Diana Whitaker Sprandio, John Mollaee, Mehri Cotzia, Paolo Birbe, Ruth Lin, Zhao Gill, Kurren Duddy, Elizabeth Zhan, Tingting Leiby, Benjamin Reyzer, Michelle Cognetti, David Luginbuhl, Adam Tuluc, Madalina Martinez‐Outschoorn, Ubaldo Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial |
title | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial |
title_full | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial |
title_fullStr | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial |
title_full_unstemmed | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial |
title_short | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial |
title_sort | metformin effects on head and neck squamous carcinoma microenvironment: window of opportunity trial |
topic | Head and Neck |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515672/ https://www.ncbi.nlm.nih.gov/pubmed/28185288 http://dx.doi.org/10.1002/lary.26489 |
work_keys_str_mv | AT curryjoseph metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT johnsonjennifer metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT tassonepatrick metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT vidalmarinadomingo metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT menezesdianawhitaker metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT sprandiojohn metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT mollaeemehri metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT cotziapaolo metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT birberuth metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT linzhao metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT gillkurren metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT duddyelizabeth metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT zhantingting metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT leibybenjamin metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT reyzermichelle metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT cognettidavid metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT luginbuhladam metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT tulucmadalina metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial AT martinezoutschoornubaldo metformineffectsonheadandnecksquamouscarcinomamicroenvironmentwindowofopportunitytrial |